AB 1906 amends California law to add annual cervical cancer screening home test kits to the list of covered preventive services. For health care service plans regulated by the Department of Managed Health Care and for disability/health policies regulated by the Department of Insurance, the bill requires coverage of a home test kit when a patient’s health care provider refers it — and forbids any deductible, coinsurance, copayment, or other cost sharing for that coverage beginning January 1, 2027.
The bill also makes home test kits a covered Medi‑Cal benefit as of January 1, 2027, with an explicit prohibition on cost sharing or spend‑down for beneficiaries to the extent federal law allows. The statutory changes are narrow in scope but raise practical questions about provider referral workflows, FDA/CLIA regulatory fit for home kits, claim coding, and who actually supplies and processes the kits — all issues payers and providers will need to resolve before implementation.
At a Glance
What It Does
AB 1906 adds 'annual cervical cancer screening home test kits' to required benefits in three California codes, requiring commercial plans and disability policies to cover the kits without cost sharing upon a provider referral starting January 1, 2027. It also makes the kits a Medi‑Cal covered benefit with no beneficiary cost sharing to the extent federal rules permit.
Who It Affects
DMHC‑regulated health care service plans, CDI‑regulated disability/health insurers, Medi‑Cal (fee‑for‑service and managed care), primary care clinicians (physicians, nurse practitioners, certified nurse‑midwives) who issue referrals, and manufacturers/labs that supply or process at‑home kits.
Why It Matters
The bill extends the state’s preventive screening mandate into the at‑home testing space, moving payers to cover an alternative delivery channel for cervical cancer screening and potentially expanding access for under‑screened populations — while creating new administrative, regulatory, and fiscal questions for plans, Medi‑Cal, and providers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 1906 inserts annual cervical cancer screening home test kits into California’s existing preventive‑screening coverage requirements. For commercial health care service plans and disability/health insurance policies, coverage is triggered when a patient’s physician, nurse practitioner, or certified nurse‑midwife refers the kit; the statute expressly bars any form of deductible, coinsurance, copayment, or other cost sharing for that benefit.
The modification sits alongside earlier requirements that already cover in‑clinic Pap tests and FDA‑approved HPV screening tests.
For Medi‑Cal, the bill makes home test kits a covered benefit beginning January 1, 2027, again for screening or diagnostic purposes upon a provider referral. The bill adds an explicit rule that beneficiaries cannot be charged any cost sharing — including share‑of‑cost or spend‑down — for the covered kit, and it applies in both fee‑for‑service and managed care delivery systems, subject to federal law where applicable.Operationally, the statute creates several practical tasks for payers and providers: plans must determine how to make kits available and paid for (direct supply, pharmacy/network dispensing, or reimbursement), update plan contracts and provider billing rules, and establish claim codes and prior‑authorization or referral verification workflows.
For Medi‑Cal, the Department of Health Care Services will need to reconcile state coverage with federal Medicaid requirements and adjust managed care contracts and fee schedules where necessary.The bill preserves certain carve‑outs found elsewhere: it exempts specialized health care service plans from the requirement and, for disability insurance, does not apply to a list of product types such as vision‑only, dental‑only, long‑term care, and other specified products. Finally, because Knox‑Keene regulated plans face criminal penalties for willful violation, the change carries enforcement teeth for DMHC‑regulated entities; the bill also includes a constitutional clause stating no state reimbursement is required for local agencies because the only local costs arise from changes to criminal provisions.
The Five Things You Need to Know
Effective date: coverage obligations for home test kits begin January 1, 2027, for commercial plans, disability policies, and Medi‑Cal.
No cost sharing: the bill forbids deductibles, coinsurance, copayments, or any other cost sharing on coverage for an annual cervical cancer screening home test kit.
Provider referral required: coverage is available only upon referral from a patient's physician and surgeon, nurse practitioner, or certified nurse‑midwife.
Exemptions: the mandate excludes specialized health care service plans and certain insurance products (e.g.
vision‑only, dental‑only, long‑term care, Medicare supplement) listed in the Insurance Code.
Medi‑Cal protections: Medi‑Cal beneficiaries cannot be charged share‑of‑cost or spend‑down for the home test kit, and the benefit applies in both fee‑for‑service and managed care arrangements, subject to federal law.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds home test kits to DMHC plan preventive coverage and bans cost sharing
This section amends the Knox‑Keene preventive coverage provision to require individual and group health care service plans (excluding specialized plans) to cover an annual cervical cancer screening home test kit upon a provider referral, and it prohibits any deductible, coinsurance, copayment, or other cost sharing for that benefit. Practically, DMHC‑regulated plans will need to revise evidence of coverage, provider manuals, and claims systems to reflect the new no‑cost benefit and to define operational channels for kit distribution and lab processing.
Extends the mandate to disability/health insurance policies with listed product exceptions
This amendment requires disability insurance policies that cover hospital, medical, or surgical benefits to cover a home test kit on provider referral without cost sharing. The section retains an exclusions list: vision‑only, dental‑only, accident‑only, specified disease, hospital indemnity, Medicare supplement, CHAMPUS supplement, long‑term care, and disability income insurance are outside the mandate, and accident‑only/hospital indemnity/specified disease policies are only affected to the extent the benefits match other covered benefits.
Adds home test kits to Medi‑Cal benefits and eliminates beneficiary cost sharing
For Medi‑Cal, home test kits become a covered screening or diagnostic benefit when a clinician refers them, effective January 1, 2027, 'to the extent required or permitted by federal law.' The statute explicitly bars any cost sharing, including share‑of‑cost or spend‑down, and covers both fee‑for‑service and managed care delivery systems. Administratively, DHCS will have to determine state plan amendment needs, establish billing/coverage rules for managed care plans, and verify federal match implications.
No state reimbursement under Article XIII B
This technical clause states that the act does not trigger state reimbursement obligations to local agencies under the California Constitution because any local costs would stem from the bill’s creation or alteration of criminal infractions under Knox‑Keene. The clause anticipates the fiscal framing used when a bill changes enforcement or penalties rather than creating an ordinary local‑cost mandate.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Under‑screened patients and people who prefer home testing: removing cost barriers and enabling an at‑home option can increase screening uptake among those who face clinic access, transportation, or scheduling barriers.
- Medi‑Cal beneficiaries specifically: the statute forbids share‑of‑cost and spend‑down charges for the kit, protecting low‑income enrollees from out‑of‑pocket expenses for this screening.
- Primary care clinicians, nurse practitioners, and certified nurse‑midwives: the bill formalizes a referral pathway that lets these providers offer a home testing alternative, which can simplify outreach and follow‑up in primary care settings.
- Manufacturers and labs that supply or process home kits: a statutory coverage mandate creates a clearer reimbursement pathway and likely expands market demand for FDA‑cleared home screening products and associated laboratory services.
- Public health programs and cancer‑prevention advocates: wider screening access could improve early detection rates and reduce long‑term treatment costs and morbidity associated with cervical cancer.
Who Bears the Cost
- DMHC‑regulated health plans and CDI‑regulated insurers: plans must pay for kits and administrative costs of distribution, claims processing, provider education, and potential contracting with vendors or labs.
- The Medi‑Cal program and state budget: while federal matching may cover part of the cost, state administrators will face upfront operational and contracting costs and possible long‑term fiscal pressure depending on utilization.
- Managed care plans and provider organizations: plans and providers will incur administrative burdens to implement referral verification, shipping/distribution logistics, and integration of lab result workflows into EHRs.
- Small insurers and niche products that must comply: although some product types are exempt, entities offering covered products will see compliance costs to update documents, notices, and systems.
- Regulatory and oversight bodies (DMHC, CDI, DHCS): these agencies must issue guidance, audit compliance, and potentially enforce the no‑cost requirement, which increases their workload without an appropriation in the bill.
Key Issues
The Core Tension
The central tension is between widening no‑cost access to an at‑home screening option — which can reach under‑screened populations — and shifting complex regulatory and fiscal burdens onto payers and Medicaid without specifying operational mechanics; the policy trades clearer access for operational ambiguity and potential cost shifting that may impede seamless implementation.
The statute ties coverage to a provider referral and to existing federal constraints for Medi‑Cal ('to the extent required or permitted by federal law'), which creates an initial implementation ambiguity: if a particular home test kit lacks explicit FDA clearance for self‑collection or if federal Medicaid rules require state plan amendments for certain supply models, coverage and federal match could be delayed or limited. Similarly, clinical laboratory regulations (CLIA) and chain‑of‑custody rules for home‑collected specimens will influence how kits can be processed and reimbursed, but the bill does not address those regulatory interactions.
The referral requirement balances medical oversight against access: it assures clinical engagement in the screening process but may create a barrier for people without an established provider relationship or for those who rely on public health outreach. The law forbids cost sharing but is silent on who supplies the kit (plan distribution, pharmacy, clinic) and how plans must reimburse manufacturers or labs; that gap will force administrative rulemaking between payers and vendors.
Lastly, enforcement has teeth for Knox‑Keene plans because willful violations remain a crime, which raises stakes for compliance but also invites questions about how regulators will monitor and adjudicate alleged noncompliance at the claims level.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.